Scott A. Smith is the Chief Executive Officer of Viatris. He joined the company’s board of directors in December 2022 and became CEO in April 2023.
Scott is a deeply knowledgeable senior global biotechnology and pharmaceutical executive with more than 35 years of experience and a proven ability to build, grow and manage large, complex organizations. His background includes substantial experience in developing and executing regulatory, clinical and business development strategies.
Before becoming CEO of Viatris, Scott served as President of BioAtla, a global biotechnology company that develops novel therapies for cancer treatment. There, he built a clinical development structure that moved multiple assets from investigational new drug applications into late-stage clinical development. He also drove the company’s long-term strategic operational plan and led all business development activities.
Scott previously served as President and Chief Operating Officer at Celgene Corporation, where he rose up the ranks with roles that included Senior Vice President and Global Head of Immunology and President of Inflammation and Immunology.
Scott earned a Bachelor of Science degree in chemistry and biology and an Honors Bachelor of Science degree in pharmacology and toxicology from Western University in Ontario, Canada, and a Master of Business Administration from Thunderbird School of Global Management in Glendale, Arizona.
He is a member of the board of directors of BioAtla and has served on the boards of multiple public and private companies including Apexigen, Titan Pharmaceuticals, Triumvira Immunologics, Refuge Biotechnologies and F-star Therapeutics.